Table 2.
Evaluation of Conventional Specimen Radiography on a margin level for the whole and for patients with clinical complete response versus no clinical complete response
| Overall cohort | Clinical complete response (cCR) | |||
|---|---|---|---|---|
| Pathologic assessment positive* | Pathologic assessment negative** | Pathologic assessment positive* | Pathologic assessment negative** | |
| CSR positive | 38 | 298 | 9 | 130 |
| CSR negative | 64 | 1772 | 29 | 834 |
| Total––no. (%) | 2172 (100%) | 1002 (100%) | ||
| (95% CI) | (95% CI) | |||
|---|---|---|---|---|
| Sensitivity––% (95% CI) | 37.3% | (35.3–39.3%) | 23.7% | (21.1–26.3%) |
| Specificity––% (95% CI) | 85.6% | (84.1–87.1%) | 86.5% | (84.4–88.6%) |
| PPV––% (95% CI) | 11.3% | (9.8–12.77) | 6.5% | (5.0–8.0%) |
| NPV––% (95% CI) | 96.5% | (95.0–98.0%) | 96.6% | (95.5–97.7%) |
| Margin conversion through CSR––no. (%) | 21 | (1.0%) | 5 | (0.5%) |
| NNT | 101 | 200 |
cCR clinical complete response, CSR Conventional Specimen Radiography, NACT neoadjuvant chemotherapy, NNT number needed to treat, NPV negative predictive value, PMR positive margin rate, PPV positive predictive value
*Tumor-infiltrated margin in histopathologic evaluation of the surgical specimen
**No tumor-infiltrated margin in histopathologic evaluation of the surgical specimen